Phase 2 Hearing Loss Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 70 years old
- You are planned to receive a high-dose cisplatin-based chemotherapy treatment, with a total planned dose above 200 mg/m² and each individual dose above 50 mg/m² (confirm with trial site if unsure about your dose)
- You may also be receiving other chemotherapy drugs at the same time, as long as those drugs are not known to cause hearing damage
- You may also be receiving radiation therapy to the base of the skull at the same time, as long as the radiation dose stays below the level that could harm hearing
- You are taking a specific type of anti-nausea medication — either Olanzapine or a type called an NK1 receptor antagonist — as part of your treatment
- You are receiving your medical care at Siriraj Hospital
Who may not be able to join:
- You have been diagnosed with nasopharyngeal carcinoma (a type of cancer at the back of the nose/throat)
- You have previously had radiation therapy to the head or neck where the dose to certain hearing-related structures (the cochlea or eustachian tube) was above specific levels (confirm with trial site)
- You have taken a medication called N-acetylcysteine (NAC) in the 2 weeks before the study begins
- You have taken certain medications known to cause hearing damage in the 2 weeks before or during the study — these include some antibiotics (aminoglycosides, vancomycin), water pills (such as furosemide), high-dose aspirin, or antimalarial drugs such as quinine
- You have a known allergy or bad reaction to acetylcysteine
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kanthong Thongyai, Master, Siriraj Hospital
Phone: 66982469575
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
- Extended high frequency audiogram - DPOAE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.